INTRODUCTION
In this update four related areas are reviewed. They are: (1) Blood Pressure (BP) definition and classification; (2) Hypertension diagnosis; (3) Hypertension and proteinuria in non-diabetic patients; and (4) Proteinuria and hypertension in the patient with diabetes.

METHODOLOGY. PubMed searches were done for papers to the above four topics published in the last five years (2014 to 2019). These were supplemented by papers from hand searches.

RESULTS
(1) BP DEFINITION AND CLASSIFICATION
BP definition
Hypertension is most commonly defined as a systolic blood pressure of ≥ 140 mm Hg or a diastolic blood pressure ≥ 90 mmHg based on three or more occasions (Abdelhafiz et al, 2018), (Weber et al, 2014). The severity of hypertension is classified into grade according to the joint statement of the European Society of Cardiology and the European Society of Hypertension (ESC/ESH) or stages according to the joint statement of the American Society of Hypertension and the International Society of Hypertension (ASH/ISH).

With the emergence of recent evidence suggesting benefits of lower BP treatment targets, the American Heart Association and the American College of Cardiology (AHA/ACC) have set the definition of hypertension as a BP of 130/80 mmHg for diagnosis (Whelton et al, 2017). Their severity classification has also been adjusted downwards. (See Table 1A) Individualisation for treatment remains important as the lower cut-offs may not be tolerated by some patients.

The MOH Clinical Practice Guideline (Tay et al, 2017) released in 2017 recommends a cut off of 140/90 mmHg for diagnosis (See Table 1B) In tandem to the adoption of the lower cut off of 130/80 mmHg mentioned above, there will be a need to make the necessary adjustments that are discussed in this update.

(2) HYPERTENSION DIAGNOSIS
Office BP measurements
Office BP readings have been accepted for diagnosis and subsequent management for several decades (Campbell & White, 2017). It is now clear that such readings are prone to inaccuracies as the result of:
- White coat hypertension – which is characterised by high office BP and normal home BP – resulting in over diagnosis and treatment;
- Masked hypertension – which is characterised by normal office BP and high home BP – resulting in under diagnosis and treatment.

There is a need for supplementary measurements with home BP monitoring (HBPM) or ambulatory BP monitoring (ABPM). HBPM or ABPM is uniquely capable of identifying patients with white coat hypertension or masked hypertension.

Ambulatory BP monitoring (ABPM) and Home BP monitoring (HBPM)
The usefulness of ambulatory blood pressure monitoring for the management is now well established. It is now not enough to
diagnose hypertension based on office BP measurements alone. These readings should be supplemented by ambulatory BP monitoring or it’s alternative of home BP monitoring (Campbell & White, 2017; Pickering, 2008).

Ambulatory BP is a stronger predictor of cardiovascular and cerebrovascular events then BP measured in the doctor’s office. Table 2 shows the definition of hypertension based on ambulatory blood pressure readings. Normal HBP measurement daytime is <135/85mmHg and night-time is 120/70 mmHg.

Home BP monitoring is an acceptable alternative when ABPM cannot be performed (Siu, 2015). There is good correlation between HBPM and ABPM for accurately diagnosing sustained normotension, white coat hypertension, and masked hypertension in both treated and untreated patients, with sensitivity ranging from 60 to 90 percent. The primary indications for HBPM are confirming elevated office BP in patients with undiagnosed hypertension and monitoring BP trends in patients with known hypertension (Liyanage-Don, 2019).

Currently, adoption of HBPM is encouraging. Sixty physicians made up of 30 General Practitioners (GP), 20 cardiologists, and 10 nephrologists were surveyed. Almost all physicians surveyed (98 percent) stated they recommended HBPM to their patients with hypertension. Overall, 81 percent of hypertensive patients were recommended to measure home BP (85 percent of those treated by cardiologists, 85 percent by nephrologists, and 76 percent by GPs) (Setia et al, 2017). Barriers to its adoption through understanding and training need to be overcome in the three stakeholders: patients, clinicians, and health system.

Hypertension in older patients
In older patients with hypertension, four phenotypes can be recognised. Besides white coat hypertension which can be seen in up to 72 percent of clinic BP readings, and masked hypertension which has a prevalence of 14-30 percent; two another types of hypertension are encountered in older patients namely, isolated systolic hypertension (BP ≥ 140/90/90 mmHg) which accounts for 60 to 80 percent of hypertension overall and prevalence increases with age; and postural hypotension (BP drop >20/10 mmHg within three minutes of standing) is common, affecting up to 20 percent of older people.

BP targets in older patients
Older people are heterogeneous in their health status. Hence, one BP target does not fit all. One strategy is to view older people to be made up of three functional categories with differ targets ranging from tight BP control in the fit person to a relaxed approach in the frail elderly. Targets need to be individualised as well as dynamic to follow the changing functional state of the patients as they age. (See Figure 1)

Figure 2 shows the special considerations in the management of hypertension in older patients namely, patients with falls risk; with dementia; are frail; have systolic hypertension; have postural hypotension; have polypharmacy associated with non-adherence; or are dependent and are staying in the home care resident setting.

**Anti-hypertensive therapy in elderly and frail populations**
Untreated, hypertension predicts worse outcomes even in the elderly and frail populations. Treatment of hypertension lowers cardiovascular morbidity and mortality in such populations. Comorbidities and frailty make management of hypertension challenging in these patients, and the approach to pharmacotherapy cannot be simplified into an algorithm like in the general population (Correa et al, 2018).

Recent guidelines now support the notion that elderly frail patients should not be precluded from anti-hypertensive therapy. Rather, physicians should individually tailor therapy after weighing the benefits of cardiovascular risk reduction against potential harmful results of such therapy. For therapeutic details on choice of drugs, the reader is referred to the paper by Correa et al, 2018.

(3) HYPERTENSION AND PROTEINURIA IN NON-DIABETIC PATIENTS

**Low-grade albuminuria in nondiabetic and normotensive individuals**
A cohort study by Tanaka et al, 2016 highlighted the important consequences of low-grade albuminuria in a cohort of 3599 individuals in Japan followed up over 5.9 years. At entry, the participants were 40 years and older, were non-diabetic and normotensive, with reserved GFR and no cardiovascular history.

Low-grade albuminuria (LGA) was found to be a predictor of the incidence cardiovascular disease and all-cause mortality in the participants. A total of 61 individuals had first Cardiovascular disease (CVD) events, and 85 individuals died.

The hazard ratios (HRs) for CVD incidence and all cause mortality in the top tertile was 2.79, with 95 percent CI of 1.41-5.52; and 1.69, with 95 percent CI of 1.00-2.84, respectively. Population-attributable fractions of the top tertile of LGA for CVD incidence and all-cause death were 37.9 and 20.1 percent respectively.

The conclusion is that in apparently healthy individuals with optimal blood pressure and no diabetes, LGA independently predicts CVD incidence and all-cause death. Low-grade albuminuria should be treated and not be ignored.

**Microalbuminuria in primary hypertension**
Microalbuminuria conventionally is defined as urinary albumin excretion between 30 and 300 mg/24 hours. Microalbuminuria is associated with left ventricular hypertrophy and carotid atherosclerosis. An emerging issue highlighted by a review of the subject by Viazzi et al, 2016 is the observed linear relationship between degree of albuminuria and left ventricular hypertrophy. Would treatment of blood pressure be able to reduce microalbuminuria and result in better and renal outcomes? More studies are needed to answer this.

Meanwhile, urine albumin excretion (UAE) is a low-cost, easy-to-use test and a powerful predictor of cardiovascular diseases.
This should be part of the routine evaluation of hypertensive patients. Treating the hypertension to ensure albuminuria is a practical treatment strategy.

Changes in albuminuria and cardiovascular risk under antihypertensive treatment

In another review paper, Viazzi et al, 201613 studied the results of trials and reported pairwise comparisons between antihypertensive treatment for cardiovascular outcome (in 16 randomised controlled trials and 48,580 patients, with a mean follow-up of 45 months, 5867 cardiovascular events).

The authors found there was a relationship between improvement in urinary albumin excretion (UAE) and blood pressure reduction. Relative risks (RR) pooled was 0.45, with CI 95.5 percent 0.23-0.85. No improvement in UAE was found between randomised pairs where there was no BP reduction (RR pooled 1.04, with 95 percent CI, 0.86 -1.26).

The conclusion was a reduction in UAE under antihypertensive treatment reduced risk of clinical cardiovascular events.

Proteinuria in Chronic Kidney Disease (CKD) patients

A review by Dhaybi and Bakris, 201714 on the place of mineralocorticoid antagonists (MRAs) in chronic disease patients showed that when used in conjunction with ACEIs or ARBs, proteinuria was reduced. The concern in the past was over worsening kidney function and hyperkalemia. Recent data from small studies highlight a way that MRAs may be used without fear of hyperkalemia.

MRAs are highly efficacious for further reducing albuminuria, when added to ACEIs or ARBs. Use of patiromer, a potassium-binding polymer, is well tolerated and enables the use of MRAs in people with advanced CKD. Use of patiromer has been shown to further reduce aldosterone as well as reduce BP when used with MRAs.

A novel nonsteroidal MRA, finerenone, which is associated with less hyperkalemia, is currently being tested in both renal and cardiovascular outcomes trials to examine effects on outcomes.

(4) PROTEINURIA AND HYPERTENSION IN THE PATIENT WITH DIABETES

Prevention of microalbuminuria

A recent systematic review was published in 2016 by Persson et al15 on prevention of microalbuminuria. Based on six trials (n=16,921), the authors found that ACE or ARB treatment was effective (RR = 0.84) in the prevention of development of microalbuminuria. Treatment also showed a trend towards a reduction in all cause-mortality (p =0.07).

Blood pressure targets in patients with type 2 diabetes mellitus

A review by Pavlou et al, 201816, reported that two-thirds of patients with type 2 diabetes mellitus have arterial hypertension. This major risk factor increases the incidence of both microvascular and macrovascular complications in these patients. Furthermore, the co-existence of diabetes and hypertension leads to a four-fold increased risk for cardiovascular disease compared to normotensive non-diabetic controls.

A BP target of less than 140/90 mmHg applies to most patients. Individualisation of the BP goal however is important, depending on the patient's age, medical history, and additional cardiovascular risk factors. For example, NICE (UK 2013) recommends a BP of <140/80 mmHg, but if there is retinopathy, cerebrovascular disease or microalbuminuria, the target is <130/80 mmHg.

Review of antihypertensives for treating hypertension in diabetes

A recent review by Sarafidis et al in 201717, was done on the effectiveness of currently available antihypertensives used for treating hypertension in diabetes mellitus. The authors reported that several lines of evidence suggest that angiotensin converting enzyme inhibitors (ACEIs), angiotensin-receptor blockers (ARBs) and calcium-channel-blockers (CCBs) have beneficial or neutral effects on carbohydrate metabolism, whereas old beta-blockers and thiazide diuretics have not. Thiazide diuretics and conventional beta-blockers were shown to reduce insulin sensitivity and to raise the risk of new onset DM.

Renal outcome trials clearly suggest that in proteinuric diabetic CKD patients, ACEIs, and ARBs reduce the rate of disease progression. Thus, an ACEI or an ARB, if tolerated, should be the first choice in diabetic individuals, followed by CCBs, vasodilating beta-blockers and diuretics, depending on the individual patient characteristics.

Recent studies also suggest that the new antidiabetic class of sodium-glucose co-transporter 2 inhibitors may offer a small reduction in BP together with important decrease in incidence of cardiovascular and renal events in patients with type 2 diabetes mellitus. In the Empagliflozin Cardiovascular Outcomes and-Mortality in Type2 diabetes (EMPA-REG OUTCOME) trial, the sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin reduced cardiovascular and renal events in type 2 DM, a result that was attributed in part to the small but sustained BP decrease throughout the trial.

Management of hypertension in diabetic nephropathy: how low?

A study by Epstein & Sowers in 199218 found that hypertension was twice as prevalent in patient with diabetes compared to the general population with the mean blood pressure rising by 5-8 percent a year in those with overt nephropathy. They found that hypertension affected 35 percent of type 1 and 25 percent of type 2 diabetic patients.

A review by Sternlicht and Bakris, 201619 concluded that taken together, current data indicate that a blood pressure goal of less than 140/90 mmHg can optimally slow CKD progression in diabetic nephropathy. Blood pressure levels of less than 130/80 mmHg are indicated in those with an estimated Glomerular filtration rate (GFR) of less than 60 and more than 500 mg of urinary protein, although the evidence is based exclusively on
retrospective analysis and is weaker than the 140/90 mmHg goal.

Sternlicht and Bakris also noted that dual RAAS blocking therapy is contraindicated in all populations, since it increases the risk for hyperkalemia, vulnerability to acute kidney injury, and may increase the risk for all-cause mortality.

**DISCUSSION**

With regards to BP definition, the current cut off of 140/90 mmHg can be reduced to 130/80 mmHg to improve cardiovascular and renal outcomes as reduce all-cause mortality.

The diagnosis of hypertension should no longer be based only on office BP readings alone but should be supplemented by home BP monitoring or ambulatory BP monitoring.

Hypertension in older patients should be treated to prevent worse outcomes but individualisation is important. Older patients are heterogeneous in health status and deciding on the degree of control based on function categories is a strategy.

<table>
<thead>
<tr>
<th>Category</th>
<th>Systolic BP</th>
<th>Diastolic BP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal BP</td>
<td>&lt; 130 mmHg</td>
<td>&lt; 85 mmHg</td>
</tr>
<tr>
<td>High-normal BP</td>
<td>130 to 139 mmHg</td>
<td>85 to 89 mmHg</td>
</tr>
<tr>
<td>Grade 1 hypertension</td>
<td>140 to 159 mmHg*</td>
<td>90 to 99 mmHg</td>
</tr>
<tr>
<td>Grade 2 hypertension</td>
<td>160 to 179 mmHg*</td>
<td>100 to 109 mmHg</td>
</tr>
<tr>
<td>Grade 3 hypertension</td>
<td>≥ 180 mmHg*</td>
<td>≥ 110 mmHg</td>
</tr>
<tr>
<td>Isolated systolic hypertension</td>
<td>≥ 140 mmHg*</td>
<td>&lt; 90 mmHg</td>
</tr>
</tbody>
</table>

* Isolated systolic hypertension is graded according to the same level of systolic BP.
Table 2. Definitions of hypertension in HBPM and ABPM

<table>
<thead>
<tr>
<th></th>
<th>Systolic BP</th>
<th>Diastolic BP</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBPM</td>
<td>≥ 135 mmHg</td>
<td>≥ 85 mmHg</td>
</tr>
<tr>
<td>ABPM Daytime</td>
<td>≥ 135 mmHg</td>
<td>≥ 85 mmHg</td>
</tr>
<tr>
<td>ABPM 24-hour</td>
<td>≥ 130 mmHg</td>
<td>≥ 80 mmHg</td>
</tr>
<tr>
<td>ABPM Night-time</td>
<td>≥ 120 mmHg</td>
<td>≥ 70 mmHg</td>
</tr>
</tbody>
</table>

Source: MOH CPG: Hypertension (Tay JC et al, 2018)4
HBPM = Home BP Monitoring; ABPM = Ambulatory BP Monitoring

Figure 1. Suggested BP targets based on patient’s functional status

Independent
- Independent community living
- Mild comorbidities
- Target BP <130/80 mmHg

Partially dependent
- Assisted community living
- Moderate comorbidities
- Target BP <140/90 mmHg.

Fully dependent
- Care home residency with limited life expectancy
- Severe comorbidities
- Target BP <150/90 mmHg.

Source: Abdelhafiz et al, 2018¹
### Figure 2. Special considerations in the management of hypertension in older patients

**Falls**
- Risk is proportionate to intensity of therapy.
- Risk is highest on initiation of medication.

**Dementia**
- Does not improve with hypertension treatment.
- Target SBP should not be <130 mmHg.

**Frailty**
- U-shaped relation with cardiac outcome.
- Target BP should not be <140/90 mmHg.

**Postural hypotension**
- Frequent in uncontrolled hypertension.
- Nocturnal therapy may exacerbate symptoms.

**Polypharmacy**
- Associated with non-adherence.
- Regular medication review.

**Systolic hypertension**
- Less responsive to antihypertensives.
- DBP should not be <70 mmHg.

**Care home residents**
- Likely dependent.
- SBP <130 mmHg increases mortality.

Source: Abdelhafiz et al, 2018¹
REFERENCES


LEARNING POINTS

- For diagnosis of hypertension, the current cut off of 140/90 mmHg can be reduced to 130/80 mmHg to improve cardiovascular outcomes and all cause mortality.
- Diagnosis of hypertension should not be based on office BP readings alone.
- Hypertension in older patients should be treated to prevent worse outcomes and should be individualised.
- In non-diabetic patients, both low grade and microalbuminuria needs to be treated; adequate BP control is needed to prevent cardiovascular outcomes and all cause mortality.
- In the diabetic patient, a BP target of less than 140/90 mmHg applies to most patients but individualisation of the BP goal is important.